Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus valsartan in heart failure with preserved ejection fraction
2013-001747-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing LCZ696 arm with Valsartan arm (2 arms). Primary endpoint: Composite of cardiovascular death and total heart failure hospitalizations. Started Aug 2013; status: completed.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2013-001747-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001747-31.